As a proof-of-concept, we designed a bi-modular system that combines a Her2-targeting module (Her2 is a receptor tyrosine protein kinase, also called erbB-2, Her2/neu), which has been shown to be over-expressed in certain breast cancers [17]), with a nucleoside-analog activating module. The gene discussed is ERBB2; the disease is breast carcinoma.